MétaCan
Menu
Back to cohort
Record W4412629771 · doi:10.1007/s40487-025-00357-z

The Health Impact of Using Anti-PD-1 Agents to Treat Early-Stage Cancer in Belgium

2025· article· en· W4412629771 on OpenAlexaff
André Bento‐Abreu, Saar Vandekeere, Demet Sönmez, Carolina Lara Neves, Tyler Mantaian, Olivier Ethgen, Raquel Aguiar‐Ibáñez

Bibliographic record

VenueOncology and Therapy · 2025
Typearticle
Languageen
FieldMedicine
TopicCancer Immunotherapy and Biomarkers
Canadian institutionsMerck Canada Inc. (Canada)
FundersMerck
KeywordsStage (stratigraphy)CancerMedicineInternal medicineBiology

Abstract

fetched live from OpenAlex

INTRODUCTION: Anti-PD-1 agents, inhibitors of programmed cell death protein 1 (PD-1), significantly improve clinical outcomes and overall survival for individuals with several metastatic and early-stage cancers. This study evaluates the health impact of using anti-PD-1 agents for early-stage disease (ESD) treatment of melanoma (stage IIB-C and III), renal cell carcinoma (RCC), and triple-negative breast cancer (TNBC) in Belgium (2023-2032). METHODS: Belgian individuals eligible for ESD treatment (target population) entered a Markov-based health outcomes model in a recurrence/event/disease-free state. The model compared anti-PD-1 agents only for metastatic disease treatment (reference scenario) versus anti-PD-1 agents for ESD treatment (ESD scenario) from 2023 to 2032. Clinical outcomes of the model included recurrence/event/disease-free life-years (LYs), total LYs, quality-adjusted LYs (QALYs), recurrences/events, active treatments for metastatic disease, and total deaths. The cumulative health impact of ESD anti-PD-1 treatment in Belgium was calculated as the difference in health outcomes between the ESD and reference scenarios for the time horizon. RESULTS: Of the 14,306 eligible individuals, 11,065 were predicted to initiate treatment with anti-PD-1 agents for ESD. Anti-PD-1 therapies for ESD increased recurrence/event/disease-free LYs (+13.4%), total LYs (+4.4%), and QALYs (+4.9%) after 10 years. Additionally, ESD treatment decreased recurrences/events (-24.6%), active treatments for metastatic disease (-28.6%), and total deaths (-23.8% decrease) over 10 years. CONCLUSIONS: The investment in and use of innovative anti-PD-1 agents for the treatment of early-stage cancers would have a positive health impact for Belgium and align with the high standards in cancer care called for in Europe's Beating Cancer Plan.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.445
Threshold uncertainty score0.999

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.046
GPT teacher head0.447
Teacher spread0.401 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations4
Published2025
Admission routes1
Has abstractyes

Explore more

Same venueOncology and TherapySame topicCancer Immunotherapy and BiomarkersFrench-language works237,207